

PMDS CEO and founder Myles Murray transfers his personal shares in the company to a Swedish holding company

PMDS Device Solutions (PMDS) today announced its CEO and founder Myles Murray has transferred his personal holding in the company to a Swedish holding company.

Mr. Murray owns in total 8,081,909 shares in the company, representing 38.76 per cent of the capital. The transfer was completed on 12th June 2024 for a total of 7 950 987,00 shares. Mr. Murray is the sole owner of the new holding company.

For additional information, please contact

Myles Murray, CEO

Phone: +353 86 887 4994

E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com

The Company's Certified Adviser is Redeye.

Information about PMDS

PMDS Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital and homecare setting. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company's shares are listed on Nasdaq First North Growth Market (STO: PMDS).

Attachments

[PMDS CEO and founder Myles Murray transfers his personal shares in the company to a Swedish holding company](#)